|
Sign In to gain access to subscriptions and/or personal tools.
|
Oxymetholone: III. Evaluation in the p53+/- Transgenic Mouse Model
Raymond E. Stoll
Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut 06877
Henry E. Holden
Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut 06877
Curt H. Barthel
Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut 06877
Kerry T. Blanchard
Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut 06877
Oxymetholone has been identified as a suspected nongenotoxic carcinogen and has recently completed testing in a conventional National Toxicology Program (NTP) 2-yr rodent bioassay program. As a synthetic androgen with a limited historical database in toxicology, oxymetholone is an ideal candidate for prospective examination of the performance of short-term transgenic mouse models in the detection of carcinogenic activity. In the present series of 3 articles, studies are described where oxymetholone was evaluated prior to disclosure of the results of the NTP 2-yr bioassay. The accompanying articles provide evidence showing that oxymetholone is devoid of mutagenic activity yet elicits a positive carcinogenic response in the Tg.AC transgenic mouse model. In the present study, oxymetholone was administered by oral gavage to p53 heterozygous male and female mice for 26 wk at doses of 125, 625, and 1,250 mg/kg/day. The vehicle was 0.5% aqueous methylcellulose. Positive controls consisted of mice treated daily by oral gavage with 200 or 400 mg/kg/day of p-cresidine in corn oil. The oxymetholone-treated females showed significantly increased body weight gain and clitoral enlargement attributable to drug treatment. In addition, significant alterations in kidney, liver, and testis weights were attributable to oxymetholone. However, there were no neoplastic lesions that were attributable to oxymetholone in either sex. p-Cresidine produced unequivocal bladder neoplasms in both sexes at the high dose and in males at the lower dose. The absence of a neoplastic response with oxymetholone is consistent with the selectivity of the p53+/- mouse model for detecting carcinogens that act by genotoxic mechanisms.
Key Words: Oxymetholone • p53+/- • transgenic • carcinogenicity • p-cresidine • bladder tumors
References
- Bootman J. (1996). Speculations on the rodent carcinogenicity of 30 chemicals currently under evaluation in rat and mouse bioassays organized by the U.S. National Toxicology Program. Environ. Mol. Mutagen. 19: 237-243.
- Donehower L., Harvey M., Slagle B., McArthur M., Montgomery C., Butel J., and Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215-221.[CrossRef][Medline]
[Order article via Infotrieve]
- Holden HE, Stoll RE, and Blanchard KT (1999). Oxymetholone: II. Evaluation in the Tg.AC transgenic mouse model for detection of carcinogens. Toxicol. Pathol. 27: 507-512 (this issue).[Abstract/Free Full Text]
- Holden HE, Studwell D., and Majeska JB (1999). Oxymetholone: I. Evaluation in a comprehensive battery of genetic toxicology and in vitro transformation assays. Toxicol. Pathol. 27: 501-506 (this issue).[Abstract/Free Full Text]
- Kastan M., Zhan Q., el-Deiry W., Carrier F., Jacks T., Walsh W., Plunkett B., Vogelstein B., and Fornace A. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lane D. (1992). p53, guardian of the genome. Nature 358: 15-16.[CrossRef][Medline]
[Order article via Infotrieve]
- Mahler J., Flagler N., Malarkey D., Mann P., Haseman J., and Eastin W. (1998). Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol. Pathol. 26: 501-511.[Abstract/Free Full Text]
- National Cancer Institute (1979). Bioassay of p-Cresidine for Possible Carcinogenicity. Carcinogenesis Technical Report Series No. 142, National Cancer Institute, Bethesda, Maryland.
- National Toxicology Program (1998). Management Status Report, April. Department of Health and Human Services, National Institutes of Health, National Institute for Envionmental Health Sciences, Research Triangle Park, North Carolina, p. 13.
- Rosenkrantz H. and McCoy E. (1981). meta-Cresidine, para-Cresidine. Contract No. I-CP 65855. Division of Cancer Causes and Prevention, National Cancer Institute, Bethesda, Maryland, pp. 1-10, 871-879.
- Tennant RW, French JE, and Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 103: 942-950.[Web of Science][Medline]
[Order article via Infotrieve]
- Tennant RW, Spalding JW, and French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and non-carcinogens. Mutat. Res. 365: 119-127.[Web of Science][Medline]
[Order article via Infotrieve]
Toxicologic Pathology, Vol. 27, No. 5,
513-518 (1999)
DOI: 10.1177/019262339902700503
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. French, R. D. Storer, and L. A. Donehower
The Nature of the Heterozygous Trp53 Knockout Model for Identifi cation of Mutagenic Carcinogens
Toxicol Pathol,
January 1, 2001;
29(1_suppl):
24 - 29.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. D. Storer, J. E. French, J. Haseman, G. Hajian, E. K. Legrand, G. G. Long, L. A. Mixson, R. Ochoa, J. E. Sagartz, and K. A. Soper
p53 +/- Hemizygous Knockout Mouse: Overview of Available Data
Toxicol Pathol,
January 1, 2001;
29(1_suppl):
30 - 50.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. C. Eastin, J. H. Mennear, R. W. Tennant, R. E. Stoll, D. G. Branstetter, J. R. Bucher, B. Mccullough, R. L. Binder, J. W. Spalding, and J. F. Mahler
Tg.AC Genetically Altered Mouse: Assay Working Group Overview of Available Data
Toxicol Pathol,
January 1, 2001;
29(1_suppl):
60 - 80.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. E. Holden, D. Studwell, and J. B. Majeska
Oxymetholone: I. Evaluation in a Comprehensive Battery of Genetic Toxicology and In Vitro Transformation Assays
Toxicol Pathol,
September 1, 1999;
27(5):
501 - 506.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. E. Holden, R. E. Stoll, and K. T. Blanchard
Oxymetholone: II. Evaluation in the Tg.AC Transgenic Mouse Model for Detection of Carcinogens
Toxicol Pathol,
September 1, 1999;
27(5):
507 - 512.
[Abstract]
[PDF]
|
|
|
|
|
